Tennant F S, Tate J A, Ruckel E
Drug Alcohol Depend. 1976 Jun;1(5):329-37. doi: 10.1016/0376-8716(76)90035-1.
Oxilorphan (levo-BC-2605) is a new, long-acting, narcotic antagonist that has agonist properties. Twenty-one (21) heroin addicts in Los Angeles were detoxified and given at least one oral dose of oxilorphan. Only three (14.3%) patients took daily doses for 14 days, which was the maximal time allowed for oxilorphan administration in this study. The remainder discontinued oxilorphan because of subjective side effects or for unknown reasons. Side effects most responsible for dropouts were dysphoria, insomnia, weakness, hallucinations, nausea, drowsiness and anorexia. Oxilorphan provided 24-hour protection with a single, oral dose, but subjective side effects encountered during inductiolinical trials with oxilorphan should be attempted with other addict populations to fully determine its potential therapeutic value.
氧吗啡烷（左旋-BC-2605）是一种新型长效麻醉拮抗剂，具有激动剂特性。洛杉矶的21名海洛因成瘾者接受了戒毒治疗，并至少口服了一剂氧吗啡烷。只有3名（14.3%）患者连续14天每日服药，这是本研究中允许使用氧吗啡烷的最长时间。其余患者因主观副作用或不明原因停用了氧吗啡烷。导致停药的最主要副作用是烦躁不安、失眠、虚弱、幻觉、恶心、嗜睡和厌食。氧吗啡烷单次口服剂量可提供24小时保护，但在诱导临床试验中遇到的主观副作用，应在其他成瘾人群中进行尝试，以充分确定其潜在治疗价值。
